The Lumina Akkolens Accommodative Iol, Complications Along 1St Postoperative Year Of Implantation
Published 2025 - 43rd Congress of the ESCRS
Reference: PP01.06 | Type: Poster | DOI: 10.82333/twap-fq67
Authors: Simone Pirodda* 1 , Jorge Alió 2 , Antonio Martinez-Abad 1 , Jorge Alio del Barrio 3 , Ana Belen Plaza-Puche 1 , Pilar Yebana 1
1Vissum Grupo miranza,Alicante,Spain, 2Vissum Grupo Miranza,Alicante,Spain;Division of Ophthalmology,Universidad Miguel Hernández,Alicante,Spain, 3Vissum Grupo miranza,Alicante,Spain;Division of Ophthalmology,Universidad Miguel Hernández,Alicante,Spain
Purpose
To report complications observed in a consecutive case series observed with the sulcus implantation of the Lumina Accommodative Intraocular Lens (AkkoLens Clinical b.v., Breda, The Netherlands).
Setting
Vissum Grupo Miranza, Alicante, Spain
Methods
This prospective multicenter descriptive study included 103 eyes (71 patients) implanted with the Akkolens Lumina IOL, including 6 eyes for refractive lens exchange (RLE). All patients were evaluated at 5 regular postoperative visits during a follow-up period of 12 months and data were collected from two clinical centers. Visual acuity, autorefractometry, slit-lamp biomicroscopy, anterior segment tomography, OCT, UBM, gonioscopy, and tonometry were performed.
Results
The overall complication rate during the one-year follow-up was 7.76% at one month, 0.97% at three, 0.97% at six and 4.85% at twelve months. The most common complications observed were corneal edema (1.94% at one month), IOL decentration (3.88% at one month, 0.97% at twelve months), pigment dispersion in the anterior chamber (1.94% at one month, 0.97% at three months, and 3.88% at twelve months) and IOP elevation was noted in 0.97% at six months. Despite complications, these patients gained excellent visual outcomes at the last visit: UDVA (LogMAR: -0.01 ± 0.05), CDVA (LogMAR: 0.06 ± 0.03), UNVA (LogMAR: 0.36 ± 0.25), CNVA (LogMAR: 0.00 ± 0), and CDNVA (LogMAR: 0.32 ± 0.17).
Conclusions
Most complications associated with the implantation of the Akkolens Lumina IOL were transitory and showed a decreasing trend over time, except for some late-onset issues such as pigment dispersion. This highlights the need for careful patient selection and prolonged patient monitoring, essential to minimize risks. Since excellent visual outcomes were achieved, it is a viable option for patients seeking improved accommodation.